The Food and Drug Administration\u2019s unprecedented approval of Florida\u2019s plan to import drugs from Canada was made possible only after Alex Azar, as the Trump administration\u2019s Health and Human Services secretary, certified that bringing medicines over the border could be done safely.<\/p>\n

Azar made the historic declaration in September 2020, just two months before his boss, former President Donald Trump, lost reelection.<\/p>\n

Now, Azar\u2019s involved in the business of making importation happen. He is chairman of the board of LifeScience Logistics, a Dallas-based company that Florida is paying as much as $39 million to help manage its Canadian drug importation program, not including the cost of drugs.<\/p>\n

LifeScience officials confirmed Azar\u2019s position but didn\u2019t respond to questions about how much he is paid or whether he\u2019s involved in the Florida work. Azar didn\u2019t return messages left with his employers or sent to a personal email address.<\/p>\n

The revolving door between government and private sector jobs is well documented. It\u2019s common for top U.S. officials in both parties to leave government service for what are often far better-paid jobs or board seats at companies in the industries they formerly regulated.<\/p>\n

About 57% of presidential Cabinet-level officials later served on corporate boards of directors, according to a 2019 study by researchers at Boston and Harvard universities in The Journal of Politics, which examined 84 Cabinet members who served from 1992 to 2014.<\/p>\n

\u201cIn general, we favor Cabinet secretaries not going into industries which they once regulated, because the possibility of conflicts of interest are unavoidable,\u201d said Robert Weissman, president of Public Citizen, a government watchdog group.<\/p>\n

\n\t\t
\n\t\t\tEmail Sign-Up\t\t<\/a>
\n\t<\/h4>\n
\n\t\tSubscribe to KFF Health News’ free Morning Briefing.\t<\/p>\n<\/div>\n
He called Azar\u2019s case atypical because his approval of drug importation was opposed by the pharmaceutical industry, in which Azar was formerly employed. Drugmakers argue the policy puts patients at risk of consuming counterfeit medicines. Azar joined the LifeScience board in January 2022, one year after the end of Trump\u2019s term and about a year after Florida contracted with LifeScience in late 2020.<\/p>\n
Katie Hernandez, a spokesperson for LifeScience Logistics, said in a statement that the company, which manages nearly 6 million square feet of warehouse storage across 11 states, signed its deal with Florida before Azar joined the board.<\/p>\n
Ivana Katic, assistant professor of organizational behavior at the Yale School of Management, said that Azar\u2019s position at LifeScience \u201ccan appear as a conflict of interest\u201d because his policy decision as HHS secretary later benefited him professionally.<\/p>\n
Azar was a deputy secretary at HHS during the George W. Bush administration before joining pharmaceutical giant Eli Lilly and Co. as a top executive in 2007, remaining there until months before joining the Trump administration.<\/p>\n
Weissman, who supports drug importation, said he doubts Azar had any personal benefit in mind before his decision. Florida Gov. Ron DeSantis had pushed Trump<\/a> to authorize importation from Canada, and the former president had said he supported importation before Azar certified it was safe.<\/p>\n
Canadian drug importation has been the subject of decades of debate. While the U.S. does not regulate most drug costs, Canada does<\/a>, generally resulting in lower prices than across the border.<\/p>\n
In 2018, Azar called importation a \u201cgimmick\u201d because Canada\u2019s pharmaceutical market isn\u2019t large enough to meet U.S. demand. Indeed, the Canadian government has repeatedly warned the U.S. against importation, promising to block any plan that poses a risk of causing shortages in Canada.<\/p>\n
The country has implemented regulations \u201cto prohibit certain drugs intended for the Canadian market from being sold for consumption outside of Canada if that sale could cause, or worsen, a drug shortage in Canada,\u201d Health Canada, which regulates drug safety, said in a Jan. 8 statement after the FDA\u2019s approval of Florida\u2019s plan. \u201cThis includes all drugs that are eligible for bulk importation to the U.S., including those identified in Florida\u2019s bulk importation plan, or any other US state\u2019s future importation programs.\u201d<\/p>\n
Under its contract with Florida, LifeScience Logistics must buy drugs from Canadian suppliers, contract with a lab to verify their authenticity, store the medicines, and ship them to state agencies for distribution. LifeScience built a 100,000-square-foot facility in Lakeland, Florida, to warehouse drugs imported from Canada.<\/p>\n
President Joe Biden supported drug importation during his 2020 campaign, but after the election his administration moved slowly to advance the process. Colorado has an importation application pending with the FDA, while several other states have passed laws allowing for importation. DeSantis has accused the Biden administration of slow-walking a decision, and his administration filed a lawsuit over the FDA\u2019s delay.<\/p>\n
Florida\u2019s importation plan will save the state up to $180 million in the first year of the program, the state said<\/a>. The importation program wouldn\u2019t aid consumers directly. It\u2019s instead aimed at helping state agencies, including its prisons, health department, and Medicaid program, obtain lower-cost drugs for HIV and AIDS, diabetes, and other conditions.<\/p>\n
Florida\u2019s plan still faces many hurdles. On top of Canada\u2019s reluctance to participate in U.S. importation programs, some drug manufacturers have deals with Canadian wholesalers preventing them from exporting medicines, and the FDA decision is likely to face a legal challenge by drugmakers.<\/p>\n
The drug industry\u2019s major lobbying group, the Pharmaceutical Research and Manufacturers of America, or PhRMA, previously sued to stop Azar\u2019s importation decision. It\u2019s expected to file suit to block Florida\u2019s program as well.<\/p>\n
A PhRMA spokesperson declined to comment on Azar\u2019s role.<\/p>\n
\n
\n\t\t\t\t\t\t\t\t\t\t\tPhil Galewitz: <\/span>
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t pgalewitz@kff.org<\/a>,\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t@philgalewitz<\/a>\n\t\t\t\t\t\t\t\t\t<\/p>\n<\/aside>\n
\n
\n
\n\t\t\t\tRelated Topics\t\t\t<\/h3>\n
\t\t\t\t
\n\t\t\tContact Us\t\t<\/a>
\n\t\t
\n\t\t\tSubmit a Story Tip\t\t<\/a>\n\t<\/div>\n<\/section><\/div>\n